Joseph Roswarski

Years Active: 2017-2019
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph Roswarski, Mark Roschewski, Christopher Melani, Stefania Pittaluga, Andrea Lucas, Seth M Steinberg, Elaine S Jaffe, Thomas A Waldmann, Wyndham H Wilson
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Leukemia & lymphoma 60 (8) (2019)
Joseph Roswarski, Mark Roschewski, Andrea Lucas, Christopher Melani, Stefania Pittaluga, Elaine S Jaffe, Seth M Steinberg, Thomas A Waldmann, Wyndham H Wilson
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leukemia & lymphoma 59 (6) (2017)

Joseph Roswarski.css-eqlu8i{font-size:small;padding-left:4px;}